PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency

BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors have entered the clinics for their promising anticancer effect as adjuvant in chemo- and radiotherapy and as single agent on BRCA-mutated tumours. Poly(ADP-ribose) glycohydrolase (PARG) deficiency was also shown to potentiate the cytotoxicity...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Cell Int
Asıl Yazarlar: Noll, Aurélia, Illuzzi, Giuditta, Amé, Jean-Christophe, Dantzer, Françoise, Schreiber, Valérie
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2016
Konular:
Primary Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4929728/
https://ncbi.nlm.nih.gov/pubmed/27375368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-016-0333-2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller